# A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia

> **NCT04659122** · PHASE1 · TERMINATED · sponsor: **Airway Therapeutics, Inc.** · enrollment: 5 (actual)

## Conditions studied

- COVID-19
- Undefined

## Interventions

- **BIOLOGICAL:** AT-100

## Key facts

- **NCT ID:** NCT04659122
- **Lead sponsor:** Airway Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-17
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Termination / study goals reached
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659122, "A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04659122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*